Mesoblast (MEOBF) EBIT Margin (2014 - 2023)
Mesoblast's (MEOBF) quarterly EBIT Margin came in at 1387.22% in Q2 2023, down 922959.0% year-over-year from N/an in Q2 2022, and down 13.83% quarter-over-quarter from 1218.67% in Q1 2023.
Powered by 
Analysis
Mesoblast (MEOBF) EBIT Margin (2014 - 2023) Analysis & Trends
Mesoblast has disclosed EBIT Margin across 10 years of filings, most recently posting 1387.22% for Q2 2023.
- In Q2 2023, EBIT Margin fell 922959.0% year-over-year to 1387.22%; the TTM figure through Jun 2023 stood at 1366.49% (down 203615.0% YoY), while the FY2026 annual figure was 136.73%, down 10223.0% from the prior year.
- EBIT Margin came in at 1387.22% for Q2 2023 at Mesoblast, down from 1218.67% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 8595.66% in Q2 2021 to a low of 2397.36% in Q1 2019.
- Average EBIT Margin over 5 years is 117.19%, with a median of 1218.67% recorded in 2023.
- Year-over-year, EBIT Margin surged 220247 bps in 2020 and sank 922959 bps in 2023.
- Over 5 years, EBIT Margin stood at 1126.57% in 2019, then decreased by 6 bps to 1190.54% in 2020, then gained by 25 bps to 888.15% in 2021, then plunged by 62 bps to 1440.72% in 2022, then climbed by 4 bps to 1387.22% in 2023.
- Per Business Quant data, the three most recent EBIT Margin figures were 1387.22% in Q2 2023, 1218.67% in Q1 2023, and 1440.72% in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.42 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.78 Bn | 3.49 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 3.06 Bn | 3.06 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | -25,827.14% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.35 Bn | 1.55 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn | 0.56% |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -1,387.22% |
| Mar 31, 2023 | -1,218.67% |
| Dec 31, 2022 | -1,440.72% |
| Sep 30, 2022 | -1,426.21% |
| Jun 30, 2022 | 7,842.37% |
| Mar 31, 2022 | -1,255.99% |
| Dec 31, 2021 | -888.15% |
| Sep 30, 2021 | -733.64% |
| Jun 30, 2021 | 8,595.66% |
| Mar 31, 2021 | -1,558.22% |
| Dec 31, 2020 | -1,190.54% |
| Sep 30, 2020 | -2,159.16% |
| Mar 31, 2020 | -194.89% |
| Dec 31, 2019 | -1,126.57% |
| Sep 30, 2019 | -63.78% |
| Jun 30, 2019 | -1,389.17% |
| Mar 31, 2019 | -2,397.36% |
| Dec 31, 2018 | -1,601.87% |
| Sep 30, 2018 | -196.46% |
| Jun 30, 2018 | -1,368.29% |